Day Zero Diagnostics Inc. an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today that independent board member, Jeff Mirviss, has been appointed board chair.
“Jeff has been an important advisor, investor and supporter of DZD since the early days of our company and the company has benefitted greatly from his involvement and counsel,” said Jong Lee, CEO and co-founder, Day Zero Diagnostics. “Jeff’s wealth of experience in strategic investments and corporate transactions in the medtech space will be incredibly valuable as we get closer to commercialization of our first-of-its-kind diagnostic and expand long-term strategic partnerships with key industry players.”
Mr. Mirviss is a global healthcare executive with more than 30 years of experience in operational leadership roles across sales, marketing, and general management. Currently, he serves as executive vice president and president of the Peripheral Interventions business unit at Boston Scientific, one of the largest medical technology companies in the world. He also serves as a member of the Executive Committee at Boston Scientific and has enterprise level responsibilities for Latin America, Canada and the Government Affairs function. Outside of Boston Scientific, Mr. Mirviss serves on the Executive Board of AdvaMed, the industry association for medtech and diagnostic companies.
“I’m honored to be elected chair of the Day Zero Diagnostics Board of Directors and look forward to continuing to work with my colleagues on the Board, as well as the visionary team at DZD,” said Jeff Mirviss, chair, DZD Board of Directors. “DZD has a unique and valuable mission that I believe will be transformative for patient care. Their platform technology will usher in a new era of rapid diagnostics for the hospital microbiology lab that brings the full power of next generation sequencing into clinical practice.”
About Day Zero Diagnostics
Day Zero Diagnostics, Inc., based in Boston, is pioneering a new class of infectious disease diagnostics using whole-genome sequencing and artificial intelligence to revolutionize how the world fights the growing threat of antimicrobial resistance. The company’s mission is to change the way infectious diseases are diagnosed and treated by rapidly identifying both the species and the antimicrobial susceptibility profile of severe infections directly from a clinical sample without the need for a culture. Day Zero also offers a family of lab services under the epiXact® brand that utilize proprietary technologies to assist healthcare organizations manage infection outbreaks, investigate organisms of interest, and make high-impact decisions. Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and the Massachusetts General Hospital. The company has been recognized as a leading innovator by CARB-X, UCSF Health, American Association of Clinical Chemistry, MedTech Innovator, TEDMED Hive, HealthTech Arkansas, and MassChallenge HealthTech. For more information, visit the website and follow DZD on X (formerly Twitter) and LinkedIn.
